AMENDMENT

(pursuant to Article 11 of the Japanese Patent Law)

To: Commissioner of the Patent Office

1. International Application Classification: PCT/JP03/04841
2. Applicant
   Name: TEIJIN LIMITED
   Address: 6-7, Minamihommachi 1-Chome,
   Chuo-ku, Osaka-shi, OSAKA
   541-0054 JAPAN
   Nationality: JAPAN
   Country of Residence: JAPAN
3. Representative
   Name: Hideko MIHARA, Patent Attorney (9967)
   Address: c/o Teijin Intellectual Property Center Limited
   1-1, Uchisaiwaicho 2-Chome,
   Chiyoda-ku, TOKYO 100-0011 JAPAN
4. Object of the Amendment:
   Specification and Claims
5. Content of the Amendment

(1) "R^1" appearing on the 4th line of page 15 of the specification (in Japanese) should be amended to "the substituents of R^1".

(2) "hydrogen" appearing on the 5th line of page 15 of the specification should be deleted.

(3) "R^1" appearing on the 23rd line of page 557 of the claims should be amended to "the substituents of R^1".

(4) "hydrogen" appearing on the 23rd line of page 557 of the claims should be deleted.

6. List of Attached Documents

(1) Specification, page 15

(2) Claims, page 557

p15

...

(23) A compound according to any one of (17) to (22) wherein the substituents of R^1 in formula (I) above may be the same or different and each is independently a halogen, hydroxy, cyano, nitro, C_1-C_6 alkyl or C_1-C_6 alkoxy, a pharmaceutically acceptable acid adduct thereof or a pharmaceutically acceptable C_1-C_6 alkyl adduct thereof.

(24) A pharmaceutical composition with CCR3 antagonism, which comprises as an effective ingredient thereof a compound represented by formula (I) above according to any one of (1) to (23), a pharmaceutically acceptable acid adduct thereof or a pharmaceutically acceptable C_1-C_6 alkyl adduct thereof.

(25) A prophylactic and/or therapeutic composition for a disease associated with CCR3, which comprises as an effective ingredient thereof a compound represented by formula (I) above according to any one of (1) to (23), a pharmaceutically acceptable acid adduct thereof or a pharmaceutically acceptable C_1-C_6 alkyl adduct thereof.

(26) A prophylactic and/or therapeutic composition according to (25), wherein said condition is an allergic condition.

(27) A prophylactic and/or therapeutic composition according to (26), wherein said allergic condition is bronchial asthma, allergic rhinitis, atopic dermatitis, urticaria, contact dermatitis or allergic conjunctivitis.

(28) A prophylactic and/or therapeutic composition according to (25), wherein said condition is inflammatory bowel disease.

(29) A prophylactic and/or therapeutic composition according to (25), wherein said condition is AIDS (Acquired Immune Deficiency Syndrome).

(30) ...

p557

...

21. A compound according to any one of claims 17 to 20, wherein R^4 and R^5 in formula (I) may be the same or different and each is independently hydrogen, a halogen, hydroxy, cyano, nitro, carboxyl, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_2-C_7 alkoxycarbonyl, C_2-C_7 alkanoylamino, C_1-C_6 alkylsulfonyl, amino, carbamoyl, C_2-C_7 N-alkylcarbamoyl, sulfamoyl or C_1-C_6 N-alkylsulfamoyl, a pharmaceutically acceptable acid adduct thereof or a pharmaceutically acceptable C_1-C_6 alkyl adduct thereof.

22. A compound according to any one of claims 17 to 20, wherein R^4 and R^5 in formula (I) may be the same or different and each is independently a halogen, hydroxy, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_2-C_7 alkoxycarbonyl, C_1-C_6 alkylsulfonyl or C_1-C_6 N-alkylsulfamoyl, a pharmaceutically acceptable acid adduct thereof or a pharmaceutically acceptable C_1-C_6 alkyl adduct thereof.

23. (Amended) A compound according to any one of claims 17 to 22 wherein the substituents of R^1 in formula (I) above may be the same or different and each is independently a halogen, hydroxy, cyano, nitro, C_1-C_6 alkyl or C_1-C_6 alkoxy, a pharmaceutically acceptable acid adduct thereof or a pharmaceutically acceptable C_1-C_6 alkyl adduct thereof.

24 ...